α-(p-Phenylphenoxy)-bernsteinsaeure | 56926-33-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-(p-Phenylphenoxy)-bernsteinsaeure
• 英文别名: 2-(4-Phenylphenoxy)butanedioic acid
• CAS: 56926-33-1
• 化学式: C₁₆H₁₄O₅
• 分子量: 286.284
• InChiKey: SXTSGTRQFYGLFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  α-(p-Phenylphenoxy)-γ-butyrolacton 在 chromium(VI) oxide 、 硫酸 作用下， 以 丙酮 为溶剂， 生成 α-(p-Phenylphenoxy)-bernsteinsaeure
  参考文献：
  名称：

  Synthesis of ethyl 6-substituted-chroman- and -chromone-2-carboxylates. Comparative structure-activity study employing the 6-phenyl and phenoxy analogs in the triton hyperlipidemic rat model

  摘要：

  To explore the effect of lipophilicity on antilipidemic activity in the Triton WR-1339 induced hyperlipidemic rat model we synthesized the 6-cyclohexyl, phenyl, and phenoxy analogs of ethyl chroman-2-carboxylate. Results obtained were analyzed in light of the biological activity observed for the 6-chloro-substituted and unsubstituted chromans, the 6-chlorochroman-4-one ester, and the 6-chloro-, phenyl-, and phenoxychromone esters. The suggestion is made that chromones likely exert their antilipidemic effects by a somewhat different set of mechanisms than do the chromans and clofibrate. Whereas the 6-chlorochromanone ester is inactive, the 6-chlorochromone ester is active in both normal and hyperlipidemic Sprague-Dawley rats. The major differential effect was observed for ethyl 6-cyclohexylchroman-2-carboxylate which did not lower cholesterol levels but returned triglyceride levels to normal in hyperlipidemic rats.

  DOI：

  10.1021/jm00243a015

文献信息

• Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
  申请人：——

  公开号：US20020165235A1

  公开（公告）日：2002-11-07

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: 1 wherein G 1 is selected from the group consisting of a, b 1 , and b 2 2 and A and G 2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及一般为IP受体拮抗剂的化合物，其由以下式I表示： 其中G1选自a、b1和b2组成的群；A和G2如规范中定义；或其个别异构体、消旋或非消旋异构体混合物，或其药用可接受盐或溶剂。该发明还涉及含有这种化合物的药物组合物，以及它们作为治疗剂的使用方法和其制备方法。
• WITIAK D. T.; HEILMAN W. P.; SANKARAPPA S. K.; CAVESTRI R. C.; NEWMAN H. +, J. MED. CHEM. <JMCM-AR>, 1975, 18, NO 9, 934-942
  作者：WITIAK D. T.、 HEILMAN W. P.、 SANKARAPPA S. K.、 CAVESTRI R. C.、 NEWMAN H. +

  DOI：——

  日期：——
• ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1379516B1

  公开（公告）日：2005-11-16
• US6903086B2
  申请人：——

  公开号：US6903086B2

  公开（公告）日：2005-06-07
• [EN] ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS<br/>[FR] DERIVES D'ACIDE ALKOXYCARBONYLAMINOBENZOIQUE OU D'ALKOXYCARBONYLAMINO TETRAZOLYL PHENYLE COMME ANTAGONISTES DE IP
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002070500A1

  公开（公告）日：2002-09-12

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by the general formula (I), wherein G1 is selected from the groups a, b?1 and b2¿; (Formula a, b?1 and b2¿) and A and G2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, their use as therapeutic agents, and methods of preparation thereof.